Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Medtronic
Johnson and Johnson
AstraZeneca
Harvard Business School

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Natalizumab - Biologic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Recent Clinical Trials for natalizumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
EMD SeronoPhase 4
Isaac Tunez-FiñanaPhase 1/Phase 2
Maimónides Biomedical Research Institute of CórdobaPhase 1/Phase 2

See all natalizumab clinical trials

Recent Litigation for natalizumab

Identify key patents and potential future biosimilar entrants

PTAB Litigation
PetitionerDate
Swiss Pharma International AG2016-04-18

See all natalizumab litigation

Pharmacology for natalizumab
Mechanism of ActionIntegrin Receptor Antagonists

Company Disclosures: US Patents for natalizumab

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   Start Trial University of Iowa Research Foundation (Oakdale, IA) 2009-12-01 RX company
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   Start Trial University of Iowa Research Foundation (Iowa City, IA) 2005-01-30 RX company
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   Start Trial Fred Hutchinson Cancer Research Center (Seattle, WA) 2015-03-24 RX company
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   Start Trial Athena Neurosciences, Inc. (South San Francisco, CA) 2014-01-25 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for natalizumab

These patents were identified by searching patent claims

Supplementary Protection Certificates for natalizumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C00104 Luxembourg   Start Trial PRODUCT NAME: KYMRIAH - TISAGENLECLEUCEL; AUTHORISATION NUMBER AND DATE: EU/1/18/1297 20180827
C00065 Luxembourg   Start Trial PRODUCT NAME: CLADRIBINE; AUTHORISATION NUMBER AND DATE: EU/1/17/1212 20170824
C 025/2006 Ireland   Start Trial SPC 025/2006: 20070523, EXPIRES: 20200124
19C/504 Belgium   Start Trial PRODUCT NAME: TISAGENLECLEUCEL; AUTHORISATION NUMBER AND DATE: EU/1/18/1297 20180827
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
AstraZeneca
Dow
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.